## Abstract **BACKGROUND**: Several studies have evaluated maternal first trimester paroxetine use and the prevalence of congenital defects, particularly cardiac defects. To synthesize current epidemiologic information, a meta‐analysis was conducted. **METHODS**: A systematic literature search was
First-trimester use of paroxetine and congenital heart defects: A population-based case-control study
✍ Scribed by Marian K. Bakker; Wilhelmina S. Kerstjens-Frederikse; Charles H. C. M. Buys; Hermien E. K. de Walle; Lolkje T. W. de Jong-van den Berg
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 89 KB
- Volume
- 88
- Category
- Article
- ISSN
- 1542-0752
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
BACKGROUND:
There is a need for case‐control studies of the effect of paroxetine on the occurrence of specific heart defects.
METHODS:
We performed a case‐control study with data from a population‐based birth defects registry in the Netherlands. All the children born between 1997 and 2006 were selected. Cases were defined as fetuses and children with isolated heart defects, and the controls were fetuses and children with a genetic disorder with no heart defect. We excluded children for whom there was no information on maternal medication use and deceased children and fetuses who were not examined postmortem. First‐trimester exposure to paroxetine was compared between cases and controls by calculating adjusted odds ratios (AOR).
RESULTS:
We included 678 cases with isolated heart defects and 615 controls. The first trimester exposure rate was 1.5% for cases and 1.0% for controls. After excluding mothers who used paroxetine outside the first trimester, or who had used another SSRI, we found no significantly increased risk for heart defects overall (10 exposed cases; AOR, 1.5; 95% confidence interval [CI], 0.5–4.0), but we did find a significantly increased risk for atrium septum defects (three exposed cases; AOR, 5.7; 95% CI, 1.4–23.7).
CONCLUSIONS:
Our results suggest that the use of paroxetine in early pregnancy is associated with an increased risk of atrium septum defects. The results stress the importance of studying possible teratogenic effects of a drug, preferably in regard to well‐specified malformations. Birth Defects Research (Part A) 2010. © 2009 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract **BACKGROUND**: Maternal exposure to flu or fever has been associated with increased risk for neural tube defects (NTDs); however, few studies have considered the effects of medications on the effects of flu or fever. We evaluated the effect of maternal flu or fever, medication use (ant
## Abstract Two previous Hungarian intervention trials showed that periconceptional folic acid‐containing multivitamin supplementation did not change the total (birth + fetal) prevalence of cases with multiple congenital abnormalities (MCAs). However, two US observational studies found an elevated
## Abstract ## BACKGROUND: Multiple congenital abnormalities (MCAs) represent the most severe category of structural birth defects; therefore, we decided to evaluate the possible etiological factors for MCAs. ## METHODS: The population‐based large data set of the Hungarian Case‐Control Surveilla
Accurate family histories of birth defects are critical for risk assessment and etiologic investigations. Typically, information about family history of birth defects is ascertained from interviews with birth mothers of index children; however, the quality of these interviews is rarely assessed. We